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Up to 38% of pancreatic and periampullary cancer patients undergoing curative intended
surgery turn out to have incurable disease. Therefore, staging laparoscopy (SL) prior to lap-
arotomy is advised to spare patients the morbidity, inconvenience and expense of futile
major surgery. The aim of this study was to assess the added value of SL with laparoscopic
ultrasonography (LUS) and laparoscopic near-infrared fluorescence imaging (LFI).
Methods
All patients undergoing curative intended surgery of pancreatic or periampullary cancer
were included prospectively in this single arm study. Patients received an intravenous infu-
sion of 10 mg indocyanine green (ICG) one or two days prior to surgery to allow LFI. Suspect
lesions were analyzed via biopsy or resection. Follow-up visits after surgery occurred every
three months.
Results
A total of 25 patients were included. Suspect lesions were identified in 7 patients: liver
metastases (n = 2; identified by inspection, LUS, and LFI), peritoneal metastases (n = 1;
identified by inspection only), and benign lesions (n = 4; identified by inspection or LUS).
Quality of LFI was good in 67% (10/15) of patients dosed one day and 89% (8/9) dosed two
days prior to surgery. A futile laparotomy was averted in 3 patients (12%). Following SL the
primary tumor was resected in 20 patients. Two patients (10%) developed metastases
within 3 months after resection.
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Conclusions
Despite current preoperative imaging modalities metastases are still identified during sur-
gery. This study shows limited added value of LUS during SL in patients with pancreatic or
periampullary cancer. LFI was of added value due to its high negative predictive value in
case of suspect hepatic lesions identified by inspection.
Introduction
Pancreatic and periampullary cancers are dreadful diseases with a poor prognosis. At time of
diagnosis only 10% to 20% of pancreatic cancer patients is eligible for curative intended sur-
gery, but during explorative laparotomy up to 38% of those patients turn out to have distant
metastases or an unresectable primary tumor [1]. Yet, even after resection with curative
intend, 5-year survival rates are still disappointingly low between 6.8% and 32% [2]. Up to 70%
of patients with resectable pancreatic cancer suffer from distant metastases, of which the
majority occurs within 6 months after surgery [3]. These metastases may have been present
during surgery without being detected. Preoperative imaging modalities, including computed
tomography (CT) and magnetic resonance imaging (MRI), have low sensitivity for subcenti-
meter peritoneal and liver metastases [4]. Especially superficial metastases are difficult to
detect. In a disease with such a dismal prognosis, it is important to spare patients with incur-
able disease the morbidity, inconvenience and expense of futile major surgery.
The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) advocates
that staging laparoscopy (SL) should be considered in selected patients [5]. Compared to
explorative laparotomy, SL results in less postoperative pain, a shorter hospital stay and
chemo- and/or radiotherapy can be administered more often and sooner to patients [6]. The
chance of an unnecessary laparotomy in patients who appear eligible for curative resection
based on preoperative imaging decreases from 40% to 17% by performing SL [7]. Moreover, a
laparotomy is not required nowadays in case of palliative treatment; metal stents make biliary
anastomosis unnecessary and other bypass surgery can be done laparoscopically.
The yield of SL may be amplified by adding laparoscopic ultrasonography (LUS) and lapa-
roscopic near-infrared fluorescence imaging (LFI). LUS enables identification of metastases
located deep in the liver and, additionally, vascular involvement of the primary tumor can be
assessed [8]. Open-space fluorescence imaging or LFI using indocyanine green (ICG) is a safe
and easy method to identify microscopic (sub)capsular liver metastases not yet visible by any
other means [9]. Yokoyama et al. previously demonstrated that open space fluorescence imag-
ing is able to identify additional micrometastases in the liver in 16% of the patients with pan-
creatic cancer [10].
Although selection of patients for SL is being advised, there is no scientific support, nor a
consensus on which selection criteria should be used [11, 12]. The current study combines SL
with LUS and LFI and aims to determine the added value of these three modalities in all




This single arm, open label, single center clinical study protocol (S1 File) was approved on
November 29 2015 by the medical ethics review board (‘Commissie Medische Ethiek’) of the
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Leiden University Medical Center (LUMC) and conducted in concordance with the Helsinki
Declaration of 1975 (as amended in Tokyo, Venice, Hong Kong, Somerset West, Edinburgh,
Washington, and Seoul), ICH-GCP guidelines, and the laws and regulations of the Nether-
lands. The study protocol has been registered at the Netherlands National Trial Register (regis-
try number NTR6639) after enrollment of participants started, due to an administrative error.
This non-randomised study adheres to the Transparent Reporting of Evaluations with Non-
Randomised designs (TREND) guidelines (S1 Fig). The authors confirm that all ongoing and
related trials for this drug/intervention are registered. All subjects provided written informed
consent prior to the start of any study-related procedure. All patients of 18 years or older
undergoing resection of suspected pancreatic or periampullary cancer at the LUMC were eligi-
ble for inclusion. Exclusion criteria were either participation in other clinical trials or contrain-
dications for ICG administration: eGFR <55; hyperthyroidism; and allergy to iodine, shellfish
or ICG. Included patients received standard-of-care, including pancreas-specific CT utilizing a
thin-section, multi-phase technique with pancreatic phase and portal venous phase images. All
patients received water as oral contrast. Additional imaging, for example contrast-enhanced
MR with 3D-MRCP, (endoscopic) ultrasound or FDG-PET, was performed if deemed neces-
sary by the multidisciplinary team. Patients who did not provide informed consent or those
who were included in other trials still received SL, but without LUS and LFI.
Staging procedure
Patients received 4 mL 2.5 mg/mL (10 mg in total) ICG one day prior to surgery to allow intrao-
perative LFU of the liver surface. This dose and dosing time was based on previous experiences
[13]. Adverse events where collected according to the local protocol and graded using the Cla-
vien-Dindo classification. Before laparotomy, SL was performed via two ports of 10 mm and one
port of 5 mm: a subumbilical port and two ports along the planned laparotomy line. Laparoscopic
inspection of the abdomen was performed, including the parietal and visceral peritoneum, the pel-
vis, the liver, the porta hepatis, the gastrohepatic omentum, the duodenum, the transverse meso-
colon and celiac region. Second, LUS (with or without Doppler; Toshiba Aplio 300, with a
laparoscopic probe) of the liver was performed by a trained surgeon. LFI of the liver surface was
performed lastly using a high-definition fluorescence imaging system (Karl Storz GmbH & Co.
KG, Tuttlingen, Germany). Lesions with a fluorescent rim were considered suspect. Quality of
fluorescence imaging was divided into three categories: good, meaning that healthy liver was dark
and bile ducts and/or intestines were fluorescent; medium, meaning that healthy liver showed
some remaining fluorescence; or bad, meaning that the liver was either totally fluorescent or
totally dark and no fluorescence was seen in bile ducts nor intestines. The categories medium and
bad were considered insufficient for adequate fluorescence imaging. We hypothesized that chole-
stasis would decrease the quality of fluorescence imaging at one day after ICG administration. If
so, dosing time would be extended to two days before surgery.
Any lesions suspect for metastases based on inspection, LUS or LFI were sampled and ana-
lyzed, either by biopsy or by resection. In case of multiple lesions with similar appearance on
inspection, LUS and LFI, only one biopsy was taken. Histopathological examination was con-
sidered the gold standard. The surgical procedure continued via laparotomy if the tumor
appeared to be resectable and no metastases were identified.
Follow-up
Follow-up occurred according to the local standard protocol, including a visit every three
months to the surgical outpatient clinic of surgery in conjunction with the department of
oncology. A CT-scan was performed only if locoregional or metastatic disease was suspected.
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Outcomes
Main outcome of this study was the percentage of averted futile laparotomies. Secondary out-
come was the accuracy of the diagnostic modalities. Findings of SL, LUS, LFI were compared
with histopathological examination of intraoperative biopsies, findings after laparotomy and
finally, with follow-up results until at least the first visit to the outpatient clinic (i.e. approxi-
mately 3 months after surgery).
Statistics
Using A’Hern’s single-stage phase II trial design and alpha = 0.05 and power = 80%, 25
patients were needed to distinguish between an averted laparotomy rate of 30% (worth explor-
ing in a Phase III trial) and 10% or less (unacceptable outcome) [14]. This required at least six
averted laparotomies to reach the positive endpoint. Statistics were calculated using SPSS (ver-
sion 23.0, IBM Statistics, US).
Results
Patient characteristics
Twenty-five patients were included between January 2016 and April 2017 (Fig 1 and S2 File).
Patient and tumor characteristics are summarized in Table 1. Three patients received neoadju-
vant therapy. One patient was treated with gemcitabine and radiotherapy, two patients with
FOLFIRINOX. In one patient a liver metastasis was already suspected based on preoperative
imaging, but no histopathological diagnosis could be obtained. During SL a liver metastasis
was confirmed by histopathological examination. None of the patients experienced adverse
events after ICG administration. Post-operative complications did occur, but all were assessed
as related to resection of the primary tumor rather than to the SL.
Averted laparotomies and accuracy of SL
In 4 patients (16%) the surgeon decided to stop the procedure after completion of the SL due
to the detection of apparent metastases. Two patients had liver metastases, which could be
identified with inspection, LUS and LFI. One patient had developed peritoneal metastases,
which were–as expected—only visible with inspection. In the fourth patient LUS showed a sus-
pect lesion in the liver, while inspection and LFI were negative (Fig 2). Intraoperative frozen
section analysis suspected an adenocarcinoma, whereupon the surgical procedure was
stopped. The pathological diagnosis was revised postoperatively into a bile duct adenoma after
subsequent immunohistochemistry. The patient underwent a laparotomy and resection four
days later and remained without metastases up to 4.5 months of follow-up. Thus, in three
patients (12%) a futile laparotomy was averted. The positive endpoint (6 averted laparotomies)
of this study was therefore not met. Furthermore, all metastases could be identified by inspec-
tion, which made LFI and LUS in these cases unnecessary.
Three other suspect lesions were resected in three other patients during SL, but turned out
to be benign. All three were assessed as suspect based on inspection only. LFI did not result in
false-positive outcomes. Positive and negative predictive values for LFI were 100% (2/2) and
80% (4/5), respectively. Peritoneal metastases were not detected by LFI, but they are never visi-
ble since LFI visualizes obstruction of hepatic ICG clearance due to invasive tumor growth.
No new metastases were discovered after laparotomy. In 2 patients (8%) a laparotomy was
performed, but the primary tumor appeared to be locally irresectable due to vascular
involvement.
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Quality of near-infrared fluorescence imaging
Results are shown in Fig 3. Fifteen patients received their dose of ICG one day prior to surgery.
In 67% of the patients (n = 10) the quality was good, resulting in sufficient visualization of
potential liver lesions. Due to reduced ICG clearance in 20% of the patients (n = 3), the quality
was medium, while in 13% (n = 2) the liver was still completely fluorescent.
No significant differences were seen in laboratory tests for cholestasis between patients with
sufficient or insufficient quality of LFI. Due to skewed data, Wilcoxon signed-rank tests were
performed. ICG was cleared sufficiently by the liver in eight out of nine patients (89%) who
were administered ICG two days prior to surgery. The surgical procedure of one patient was
postponed after ICG administration with five days due to clinical reasons. During SL no fluo-
rescence signal was detected at all.
Fig 1. CONSORT flow diagram.
https://doi.org/10.1371/journal.pone.0205960.g001
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Follow-up
The median follow-up time of all included patients was 11.8 months (range 1.4–17.5). Liver
metastases were diagnosed in 20% (n = 5) of the patients in whom the primary tumor was
resected. In two patients, liver metastases were diagnosed within six months after surgery.
None were detected during SL or subsequent laparotomy. When including these lesions, accu-
racies of diagnostic modalities decreased to 44% (4/9), 56% (5/9) and 67% (5/9) for inspection,
LUS and LFI, respectively. In hindsight, abnormal fluorescent spots were visible in one patient
who developed miliary liver metastases (Fig 4). However, since no suspect fluorescence rim
pattern was observed, no biopsies were taken.
Discussion
Several attempts have been made to increase the yield of SL in pancreatic and periampullary
cancer patients, including use of contrast-enhanced ultrasound, LUS, and selection based on
preoperative imaging or blood values [8, 15–20]. This is the first study to combine SL with
LUS and LFI, but not with the desired result. As mentioned, an unselected population of
patients with periampullary cancer was included in this study. This may have resulted in a low
a priori probability of metastases (12%; 3/25). In hindsight, including only patients with CA
19.9> 150 U/L or a tumor sized > 3 cm, as suggested in a systematic review covering 24 stud-
ies [21], would increase the incidence to 21% (3/14). However, it remains disputable if selec-
tion of patients for SL should be performed. During this study period all patients with




Age at surgery, median (range) 67 (51–83)
Origin of primary tumor, % (n)
Pancreas 78 (17)
Duodenum 12 (3)
Ampulla of Vater 12 (3)
Distal common bile duct 8 (2)
Radiological characteristics, % (n)
� cT3� 28 (7)
cN1 16 (4)
Neoadjuvant therapy, % (n)
Chemotherapy 12 (3)
Radiotherapy 4 (1)
Adjuvant therapy, % (n) 40 (10)
Preoperative size of tumor (mm), % (n)
Not measurable 24 (6)
� 3 cm 36 (9)
< 3 cm 40 (10)
Laboratory values, median (range)
CEA (μg/L) 3.0 (0.2–18.8)
CA19.9 (kU/L) 132 (3–3426)
Total bilirubin (μmol/L) 48 (6–376)
Alkaline phosphatase (U/L) 243 (57–684)
γ-glutamyl transpeptidase (U/L) 182 (12–2159)
https://doi.org/10.1371/journal.pone.0205960.t001
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pancreatic or periampullary cancer who were not included also received SL (without LUS or
LFI) before exploratory laparotomy (data not shown). Metastases were detected in 16% (5/31)
of these patients. Two of these five patients would not have received SL with the above men-
tioned selection criteria. Risking that patients with metastases do not undergo SL should be
weighed against delaying all procedures with 10 to 15 minutes.
In surgery for colorectal liver metastases, the addition of NIRF imaging to inspection and
ultrasound doubled the intraoperative detection rate of additional liver metastases from 13%
to 25% [22]. In the current study, we aimed to increase the yield of intraoperative screening
for metastases of pancreatic or periampullary cancers by adding fluorescence imaging, but no
additional metastases were discovered solely with LFI. One issue could be that, in contrast to
patients with colorectal liver metastases, patients with pancreatic or periampullary cancer are
more likely to have reduced ICG clearance. Reduced ICG clearance results in nonspecific
background fluorescence, which can hamper detection of micrometastases. Our study suggest
that within this population dosing ICG two days prior to surgery results in improved quality of
fluorescence imaging than one day, regardless of cholestasis laboratory tests.
Apparently, LFI in patients with pancreatic or periampullary cancer has a certain learning
curve. During open-space fluorescence imaging, Yokoyama et al. [10] observed abnormal fluores-
cence spots (larger than 1.5 mm) in 4 patients, but no malignancies could be confirmed by histo-
pathological examination. Three of these patients developed liver metastases within six months.
In the current study, only a rim pattern was considered suspect, based on previous experiences
with fluorescence imaging of liver metastases [9, 13]. However, abnormal fluorescent spots were
seen in two patients (Fig 4) and both developed hepatic metastases shortly after surgery. The yield
of LFI may have been higher if also abnormal spots without a rim pattern were analyzed. Yet, LFI
was of added value to assess suspect hepatic lesions due to its high negative predictive value; none
of the three suspect lesions that turned out to be benign were fluorescent.
Fig 2. False-positive lesion. A lesion suspected to be a metastasis was detected and biopsied with laparoscopic imaging
(arrow). Near-infrared fluorescence imaging did not show any fluorescence signal, even though the lesion was located
7 mm below the liver capsule. The final diagnosis was a bile duct hamartoma.
https://doi.org/10.1371/journal.pone.0205960.g002
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LUS was expected to identify intrahepatic metastases and to assess resectability before
exploratory laparotomy. However, the technique failed to deliver. Instead, it even resulted in a
false-positive biopsy. The added value of LUS is minimized even further when combined with
MRI, which is already very sensitive for small, intrahepatic metastases [23]. However, superfi-
cial liver metastases remain difficult to distinguish on preoperative imaging. These metastases
can be detected with inspection and LFI. The current results suggest that there is no added
value of LUS during SL when optimal preoperative imaging has been performed.
In conclusion, this study showed limited added value of LUS during SL in patients with
pancreatic or periampullary cancers. Although LFI had a learning curve, it had a high negative
predictive value in case of suspect hepatic lesions identified by inspection. If ICG is adminis-
tered two days prior to surgery it may have more value in a selected patient population.
Fig 3. Quality of near-infrared fluorescence imaging. Upper fig: In the majority of patients ICG was cleared sufficiently from healthy liver tissue (star) if
administered 2 days before to surgery. The gall bladder (arrow) was used as a positive control. In 33%, the liver still showed significant background
fluorescence if ICG was administered 1 day prior to surgery. Lower fig: ICG administered 1 day showed insufficient clearance regardless of cholestatic
laboratory values.
https://doi.org/10.1371/journal.pone.0205960.g003
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